Aim immunotech to participate in solve m.e. and the biotechnology innovation organization (bio) virtual event, “long covid: what will it take to accelerate therapeutic progress?

Ocala, fla., feb. 17, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including covid-19, the disease caused by the sars-cov-2 virus — today announced it will participate in an event hosted by solve m.e. diagnostics and the biotechnology innovation organization (bio) titled, “long covid: what will it take to accelerate therapeutic progress?,” being held virtually on tuesday, february 21, 2023, from 10:00 am – 1:00 pm pt.
AIM Ratings Summary
AIM Quant Ranking